MiR-7b directly targets DC-STAMP causing suppression of NFATc1 and c-Fos signaling during osteoclast fusion and differentiation

Dou, Ce; Zhang, Chengcheng; Kang, Fei; Yang, Xiaochao; Jiang, Hong; Bai, Yan; Xiang, Junyu; Xu, Jianzhong

doi:10.1016/j.bbagrm.2014.08.002

Cited by 83 publications

(73 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, mononuclear tartrate resistant acid phosphatase (TRAP) positive cells were present in DC‐STAMP −/− mice, suggesting that osteoclastogenesis occurs without cell fusion in DC‐STAMP −/− osteoclasts 14. We previously reported that miR‐7b directly target the mRNA of DC‐STAMP thus inhibit osteoclast fusion 13. To examine if GO‐PEI‐miR‐7b has similar effect, GO‐PEI‐miR‐7b of different concentrations were introduced during RANKL‐induced osteoclastogenesis.…”

Section: Resultsmentioning

confidence: 99%

“…Relative TRAP activity was measured by colorimetric analysis. For actin cytoskeleton and focal adhesion stain, cells were cultured on glass sheet in a 12‐well plate at a density of 4 × 10 4 cells per well with RANKL (100 ng mL −1 ) and M‐CSF (50 ng mL −1 ) for 3 d. Procedures were described in previous study 13. In brief, on day 4, cells were washed and fixed for permeabilization.…”

Section: Methodsmentioning

confidence: 99%

“…These small miRNAs bind to the complementary site on the 3′ untranslated region of targeting mRNAs called miRNA binding elements and block protein translation or modulate mRNA stability on a post‐transcriptional level 12. We previously reported that miR‐7b directly targets the mRNA of dendritic cell‐specific transmembrane protein (DC‐STAMP), which is an important fusogenic molecule during osteoclast maturation 13. Overexpression of miR‐7b inhibited the expression of DC‐STAMP, without DC‐STAMP, mature osteoclast formed by cell–cell fusion will be blocked and bone resorption will be dampened.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Graphene‐Based MicroRNA Transfection Blocks Preosteoclast Fusion to Increase Bone Formation and Vascularization

et al. 2017

Self Cite

View full text Add to dashboard Cite

The objective of this study is to design a graphene‐based miRNA transfection drug delivery system for antiresorptive therapy. An efficient nonviral gene delivery system is developed using polyethylenimine (PEI) functionalized graphene oxide (GO) complex loaded with miR‐7b overexpression plasmid. GO‐PEI complex exhibits excellent transfection efficiency within the acceptable range of cytotoxicity. The overexpression of miR‐7b after GO‐PEI‐miR‐7b transfection significantly abrogates osteoclast (OC) fusion and bone resorption activity by hampering the expression of an essential fusogenic molecule dendritic cell‐specific transmembrane protein. However, osteoclastogenesis occurs without cell–cell fusion and preosteoclast (POC) is preserved. Through preservation of POC, GO‐PEI‐miR‐7b transfection promotes mesenchymal stem cell osteogenesis and endothelial progenitor cells angiogenesis in the coculture system. Platelet‐derived growth factor‐BB secreted by POC is increased by GO‐PEI‐miR‐7b both in vitro and in vivo. In treating osteoporotic ovariectomized mice, GO‐PEI‐miR‐7b significantly enhances bone mineral density, bone volume as well as bone vascularization through increasing CD31hiEmcnhi cell number. This study provides a cell–cell fusion targeted miRNA transfection drug delivery strategy in treating bone disorders with excessive osteoclastic bone resorption.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Graphene‐Based MicroRNA Transfection Blocks Preosteoclast Fusion to Increase Bone Formation and Vascularization

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…У пациентов с акромега-лией были типичные клинические проявления, в том числе изменение внешности за счет укрупнения черт лица, кистей и стоп, повышенный ИРФ-1 (возраст-ной референсный интервал уровней ИРФ-1 опреде-лялся следующим образом: [18][19][20] [9]. Пациентам с акромегалией проводилась магнитно-ре-зонансная томография головного мозга, по результатам которой подтверждено наличие аденомы гипофиза.…”

Section: материалы и методыunclassified

“…В условиях избытка СТГ и ИРФ-1 уси-ление формирования и разрушения костной ткани осуществляется в разной степени, при этом патоге-нетические аспекты данных изменений не раскрыты, что требует более глубокого изучения на молекуляр-ном уровне. Эпигенетика представляет собой изучение изменения активности генов, при которых структура ДНК остается прежней [20]. Одним из основных эпигенетических механизмов является изменение экспрессии мкРНК.…”

Section: результатыunclassified

Expression of microRNA related to bone remodeling regulation in plasma in patients with acromegaly

Grebennikova¹,

Белая²,

Никитин³

et al. 2017

Obes. metabol.

View full text Add to dashboard Cite

Backgraund. MiсroRNA are small regulatory factors that regulate gene expression by post-transcriptional regulation of mRNA, playing an important role in numerous cellular processes including organogenesis, apoptosis, cell proliferation and differentiation. Acromegaly causes bone fragility, but the pathogenetic mechanism is generally unknown. Aim. To evaluate levels of microRNA related to bone remodeling regulation in plasma samples from patients with acromegaly Materials and methods. Fasting plasma samples were taken and stored in aliquot at -80C from consecutive subjects with clinically evident and biochemically confirmed active acromegaly and healthy volunteers matched by age, sex and body mass index (BMI). miRNeasy Serum/Plasma Kit, TaqMan Advanced miRNA cDNA Synthesis Kit, TaqMan Advanced miRNA Assays were used to assay plasma miRNA expression. Insulin-like growth factor 1 (IGF1) was measured by immunochemiluminescence assay (Liaison). Results. We enrolled 40 subjects 22 patients suffered from acromegaly and 18 matched healthy controls) matched by sex, age and BMI. The median age of patients with acromegaly was 42 years (Q25;Q75 37;43) with no difference among the groups, p=0.205; BMI 28 (24;32) kg/m2, p=0.253. The median IGF1 in subjects with acromegaly 622 (514;1000) ng/ml was significantly higher as compared to the control group (p0.001). Patients with acromegaly had significantly higher expression of microRNA-100-5р (p=0.051), microRNA-550а-5р (p=0.048), microRNA-7b-5р (p=0.005) and microRNA-96-5р (p=0.042) among 27 bone-specific microRNA tested in plasma Conclusions. This study reveals that several microRNAs, known to regulate bone remodeling can be detected in plasma samples of patients with acromegaly and may be suggested as biomarkers for skeletal involvement in patients with acromegaly.

show abstract

Bioactives and Biomaterial Construction for Modulating Osteoclast Activities

He,

Jiang,

Dong

2023

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

Bone tissue constitutes 15–20% of human body weight and plays a crucial role in supporting the body, coordinating movement, regulating mineral homeostasis, and hematopoiesis. The maintenance of bone homeostasis relies on a delicate balance between osteoblasts and osteoclasts. Osteoclasts, as the exclusive “bone resorbers” in the human skeletal system, are of paramount significance yet often receive inadequate attention. When osteoclast activity becomes excessive, it frequently leads to various bone metabolic disorders, subsequently resulting in secondary bone injuries, such as fractures. This not only reduces life quality of patients, but also imposes a significant economic burden on society. In response to the pressing need for biomaterials in the treatment of osteoclast dysregulation, there is a surge of research and investigations aimed at osteoclast regulation. Promising progress is achieved in this domain. This review seeks to provide a comprehensive understanding of how to modulate osteoclast activities. It summarizes bioactive substances that influence osteoclasts and elucidates strategies for constructing related biomaterial systems. It offers practical insights and ideas for the development and application of biomaterials and tissue engineering, with the hope of guiding the clinical treatment of osteoclast‐related bone diseases using biomaterials in the future.

show abstract

MiR-7b directly targets DC-STAMP causing suppression of NFATc1 and c-Fos signaling during osteoclast fusion and differentiation

Cited by 83 publications

References 69 publications

Graphene‐Based MicroRNA Transfection Blocks Preosteoclast Fusion to Increase Bone Formation and Vascularization

Graphene‐Based MicroRNA Transfection Blocks Preosteoclast Fusion to Increase Bone Formation and Vascularization

Expression of microRNA related to bone remodeling regulation in plasma in patients with acromegaly

Bioactives and Biomaterial Construction for Modulating Osteoclast Activities

Contact Info

Product

Resources

About